Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

BMC Cancer

Research Article

Alfredo Romano¹  Josefine Römmler-Zehrer¹  Jack Shiansong Li¹  Desmond McGovern¹  Arndt Vogel²  Michael Stahl³ 

[1] Celgene Corporation, Summit, NJ, USA;Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany;Medizinische Hochschule Hannover, Ltd. Oberarzt der Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Gebäude I11, Ebene H0, Raum 1380, Carl-Neubergstr. 1, 30625, Hannover, Germany;Department of Medical Oncology, Kliniken Essen-Mitte, Essen, Germany;

关键词: Gemcitabine;    Metastatic pancreatic cancer;    nab;    Progressive disease;    Subgroup analysis;   

DOI  :  10.1186/s12885-016-2798-8

 received in 2016-04-22, accepted in 2016-09-14,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe phase 3 MPACT trial in patients with metastatic pancreatic cancer demonstrated superior efficacy of nab-paclitaxel (nab-P) + gemcitabine (Gem) vs Gem monotherapy for all endpoints examined including overall survival, the primary endpoint. In the MPACT trial, patients were treated until progressive disease (PD) or unacceptable toxicity. The current exploratory analysis investigated outcomes of patients from the MPACT trial who were treated until PD, in order to understand how to maximize treatment benefit from nab-P + Gem.MethodsThe trial design has been described in detail previously. Progressive disease was determined by the investigator on the basis of radiological imaging.ResultsAmong patients who were treated until PD, overall survival was significantly longer for those who received nab-P + Gem vs Gem (median, 9.8 vs 7.5 months; P < 0.001). Independently assessed progression-free survival and overall response rate were significantly greater among patients in the treatment-to-PD cohort who received nab-P + Gem compared with Gem (P < 0.001 for each). Although not compared statistically, patients who were treated until PD received greater treatment exposure and experienced more favourable efficacy than the intent-to-treat population of the MPACT trial. Among patients who were treated with nab-P + Gem until PD, > 50 % went on to receive a subsequent therapy. The safety profile for patients treated until PD was similar to what was reported in the overall MPACT trial.ConclusionThe nab-P + Gem regimen is an active first-line treatment option; most patients were treated until PD, and this exposure was associated with improved efficacy outcomes. Prolonged first-line treatment exposure and ability to receive subsequent therapies likely contributed to the improved survival among these patients. Our data highlight the importance of managing adverse events and indicate that patients should be treated until PD when possible.Trial registrationClinicalTrials.gov NCT00844649 (MPACT trial); Registration date of this prospective phase III trial: February 13, 2009; current exploratory subanalysis was conducted retrospectively.

【 授权许可】

CC BY   
© The Author(s). 2016